Novo Nordisk A/S vs Tapestry, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Tapestry, Inc. trades at $140.62 (market cap $28.51B). The key difference: Novo Nordisk A/S is far larger — about 7.7× Tapestry, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TPR | |
|---|---|---|
Market Cap | $220.53B | $28.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $160.49 |
52-Week Low | $35.29 | $95.69 |
Enterprise Value | $239.49B | $31.37B |
Dividend Yield | 3.63% | 1.13% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →